NEOSINUS is a drug development platform company that has commercialized a fully integrated Platform for optimizing drug delivery and health outcomes. The core platform is designed to optimize the delivery of medications to essential drug pathways and overcome physiological barriers that currently impede high potential drugs.
The company has developed a platform that will transform the delivery and effectiveness of drugs for mental health, neurological disorders, respiratory illnesses, immune system disorders, and more through strategic out-licensing partnerships and internal clinical development programs.
The company is playing a leadership role in integrating high-potential drugs, emerging nanotechnologies, and a new class of drugs that will address the largest global health burden and deliver new therapies that have been unattainable for many decades.
